Targeting the essentialome of radiotherapy-resistant cancer

Project Information

TETHER

Grant agreement ID: 883877

DOI 10.3030/883877

EC signature date 28 May 2020

Start date 1 October 2021

End date 30 September 2026

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost € 2 499 875,00

EU contribution € 2 499 875,00

Coordinated by

UNIVERSITAET BERN
Switzerland

Publications

Peer reviewed articles (13)

Meiotic Genes and DNA Double Strand Break Repair in Cancer

Author(s): Lea Lingg, Sven Rottenberg, Paola Francica
Published in: Frontiers in Genetics, 2022, ISSN 1664-8021
Publisher: Frontiers Media
DOI: 10.3389/fgene.2022.831620

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

Author(s): Bhin J, Paes Dias M, Gogola E, Rolfs F, Piersma SR, de Bruijn R, de Ruiter JR, van den Broek B, Duarte AA, Sol W, van der Heijden I, Andronikou C, Kaiponen TS, Bakker L, Lieftink C, Morris B, Beijersbergen RL, van de Ven M, Jimenez CR, Wessels LFA, Rottenberg S, Jonkers J
Published in: Cell Reports, 2023, ISSN 2211-1247
Publisher: Cell Press
DOI: 10.1016/j.celrep.2023.112538

LRP6 Is a Functional Receptor for Attenuated Canine Distemper Virus

Author(s): Gradauskaite, Vaiva; Inglebert, Marine; Doench, John; Scherer, Melanie; Dettwiler, Martina; Wyss, Marianne; Shrestha, Neeta; Rottenberg, Sven; Plattet, Philippe
Published in: mBio, 2023, ISSN 2150-7511
Publisher: American Society for Microbiology
DOI: 10.1128/mbio.03114-22

Persisting cancer cells are different from bacterial persisters

Author(s): Decollogny, Morgane; Rottenberg, Sven
Published in: Trends in Cancer, Issue 10(5):393-406, 2024, ISSN 2405-8025
Publisher: CellPress
DOI: 10.1016/j.trecan.2024.02.002

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair

Author(s): Andronikou, Christina; Burdova, Kamila; Dibitetto, Diego; Lieftink, Cor; Malzer, Elke; Kuiken, Hendrik J; Gogola, Ewa; Ray Chaudhuri, Arnab; Beijersbergen, Roderick L; Hanzlikova, Hana; Jonkers, Jos; Rottenberg, Sven
Published in: The EMBO Journal, Issue 43(6):1015-1042, 2024, ISSN 0261-4189
Publisher: Nature Publishing Group
DOI: 10.1038/s44318-024-00043-2

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

Author(s): Zelceski A, Francica P, Lingg L, Mutlu M, Stok C, Liptay M, Alexander J, Baxter JS, Brough R, Gulati A, Haider S, Raghunandan M, Song F, Sridhar S, Forment JV, O'Connor MJ, Davies BR, van Vugt MATM, Krastev DB, Pettitt SJ, Tutt ANJ, Rottenberg S, Lord CJ
Published in: Cell Reports, 2023, ISSN 2211-1247
Publisher: Cell Press
DOI: 10.1016/j.celrep.2023.112484

Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy

Author(s): Widmer CA, Klebic I, Domanitskaya N, Decollogny M, Howald D, Siffert M, Essers P, Nowicka Z, Stokar-Regenscheit N, van de Ven M, de Korte-Grimmerink R, Galván JA, Pritchard CEJ, Huijbers IJ, Fendler W, Vens C, Rottenberg S
Published in: Cancer Research Communications, 2022, ISSN 2767-9764
Publisher: American Association for Cancer Research
DOI: 10.1158/2767-9764.crc-22-0208

H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours

Author(s): Diego Dibitetto; Martin Liptay; Francesca Vivalda; Ewa Gogola; Hulya Dogan; Martín G. Fernández; Alexandra Duarte; Jonas A. Schmid; Stephen T. Durant; Josep V. Forment; Ismar Klebic; Myriam Siffert; Roebi de Bruijn; Arne N. Kousholt; Nicole A. Marti; Martina Dettwiler; Claus S. Sørensen; Massimo Lopes; Alessandro A. Sartori; Jos Jonkers; Sven Rottenberg
Published in: Nature Communications, Issue 4430 (2024), 2024, ISSN 2041-1723
Publisher: Nature Publishing Group
DOI: 10.1101/2023.05.22.541781

International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

Author(s): Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L; Consensus Panellist Group
Published in: Lancet Oncology, Issue 25(2):e73-e83, 2024, ISSN 1470-2045
Publisher: The Lancet Publishing Group
DOI: 10.1016/s1470-2045(23)00534-x

DNA-PKcs promotes fork reversal and chemoresistance

Author(s): Dibitetto D, Marshall S, Sanchi A, Liptay M, Badar J, Lopes M, Rottenberg S, Smolka MB
Published in: Molecular Cell, 2022, ISSN 1097-2765
Publisher: Cell Press
DOI: 10.1016/j.molcel.2022.08.028

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

Author(s): Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink
Published in: Nature, 2022, ISSN 0028-0836
Publisher: Nature Publishing Group
DOI: 10.1038/s41586-022-05066-5

DNA repair, gap suppression, or fork protection: BRCA2 needs a break!

Author(s): Diego Dibitetto, Sven Rottenberg
Published in: Molecular Cell, Issue 84(3):409-410, 2024, ISSN 1097-2765
Publisher: Cell Press
DOI: 10.1016/j.molcel.2023.12.026

Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids

Author(s): Paes Dias M, Rottenberg S, Jonkers J.
Published in: Star Protocols, 2022, ISSN 2666-1667
Publisher: Elsevier
DOI: 10.1016/j.xpro.2022.101132